(Q38059437)

28 August 2017

Medical therapies for hepatocellular carcinoma: a critical view of the evidence (English)

1 reference

28 August 2017

hepatocellular carcinoma

1 reference

inferred from title

author

Virginia Hernandez-Gea

series ordinal

2

1 reference

28 August 2017

3

1 reference

28 August 2017

Augusto Villanueva

1

0 references

language of work or name

English

0 references

publication date

13 November 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

28 August 2017

1 reference

28 August 2017

10

1 reference

28 August 2017

34-42

1 reference

28 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2012.199

28 August 2017

0 references

cites work

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

The genetic basis for cancer treatment decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Cancer gene discovery in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Fibrosis-dependent mechanisms of hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Resection and liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Chemoembolization for intermediate HCC: is there proof of survival benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

HBx gene of hepatitis B virus induces liver cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

To Expand or Not to Expand the Criteria for Hepatocellular Carcinoma Transplantation: Is Downstaging the Answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Cochrane Database of Systematic Reviews

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Rising incidence of hepatocellular carcinoma in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.199

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23147664

12 December 2020

inferred from PubMed ID database lookup

Expanded programme on immunization. Global Advisory Group--Part II

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23147664

12 December 2020

inferred from PubMed ID database lookup

Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23147664

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NRGASTRO.2012.199

1 reference

28 August 2017

1 reference

PubMed ID

23147664